Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) Book value per share
Bio-Techne Corp's book value per share at the end of fiscal 2026 was 13.5×, up 11.0% from 12.2× in fiscal 2025. Over the past ten years it has ranged from 5.7× (fiscal 2015) to 13.5× (fiscal 2026) — the current reading is the highest in ten years. Bio-Techne Corp ranks 60th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2026 | 13.5× | 10.97% |
| FY2025 | 12.2× | (7.14%) |
| FY2024 | 13.1× | 4.85% |
| FY2023 | 12.5× | 15.38% |
| FY2022 | 10.8× | 6.96% |
| FY2021 | 10.1× | 12.16% |
| FY2020 | 9.0× | 17.19% |
| FY2019 | 7.7× | 7.15% |
| FY2018 | 7.2× | 13.13% |
| FY2017 | 6.4× | 7.66% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 13.5× | 1.33% |
| Mar 2026 | 13.3× | 3.37% |
| Dec 2025 | 12.9× | 2.05% |
| Sep 2025 | 12.6× | 3.81% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | 32.3× |
| PCVX Vaxcyte, Inc. compare | 19.1× |
| KYMR Kymera Therapeutics, Inc. compare | 16.1× |
| TECH Bio-Techne Corp | 13.5× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| SMMT Summit Therapeutics PLC compare | 0.8× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement